Expertise in
47
conditions

Dr. Daniel Vaena

Oncology
The West Clinic PLLC
7945 Wolf River Blvd, 
Germantown, TN 
Offers Telehealth
Expertise in
47
conditions
The West Clinic PLLC
7945 Wolf River Blvd, 
Germantown, TN 

Overview

Daniel Vaena is an Oncologist in Germantown, Tennessee. Dr. Vaena is highly rated in 47 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, WT1-Related Wilms Tumor Syndromes, and Clear Cell Sarcoma.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in TN

Hospital Affiliations

Methodist Hospitals Of Memphis
Baptist Memorial Hospital
St Francis Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

The West Clinic PLLC
7945 Wolf River Blvd, Germantown, TN 38138
Other Locations
The West Clinic PLLC
7668 Airways Blvd, Southaven, MS 38671

Additional Areas of Focus

Dr. Vaena has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: TTX-030, Pembrolizumab, Docetaxel, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
Enrollment Status: Terminated
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Head and Neck Cancer
A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: June 26, 2018
Intervention Type: Dietary supplement, Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

24 Total Publications

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Journal: JAMA network open
Published: October 07, 2024
Similar Doctors
Expertise in
13
conditions
Dr. Amar Gajjar
Hematology | Oncology
Expertise in
13
conditions
Dr. Amar Gajjar
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (13.0 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances

Amar Gajjar is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Gajjar is highly rated in 13 conditions, according to our data. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

Expertise in
15
conditions
Dr. Marcin Wlodarski
Hematology | Oncology
Expertise in
15
conditions
Dr. Marcin Wlodarski
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (13.0 miles away)
888-226-4343
Languages Spoken:
English
See accepted insurances

Marcin Wlodarski is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Wlodarski is highly rated in 15 conditions, according to our data. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Dyskeratosis Congenita, Bone Marrow Transplant, and Splenectomy.

Expertise in
8
conditions
Dr. Jane Hankins
Hematology | Oncology
Expertise in
8
conditions
Dr. Jane Hankins
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (13.0 miles away)
901-595-4153
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Hankins is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Hankins is highly rated in 8 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy.

Frequently Asked Questions about Dr. Daniel Vaena

How do I make an appointment with Dr. Daniel Vaena?

You can book an appointment with Dr. Daniel Vaena by calling their office at 901-683-0055. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel Vaena a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel Vaena is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel Vaena specialize in?

While Dr. Daniel Vaena is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Urothelial Cancer, and WT1-Related Wilms Tumor Syndromes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Daniel Vaena participate in research or clinical trials?

Yes. Dr. Daniel Vaena has published 24 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Daniel Vaena's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel Vaena accept my insurance?

Dr. Daniel Vaena accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 901-683-0055 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vaena's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 34 Advanced Conditions
    View All 145 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile